American Vanguard (AVD) 10-Q 31 Jul 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 25, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	AVD
Entity Registrant Name	AMERICAN VANGUARD CORP
Entity Central Index Key	5,981
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		29,783,825

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Net sales	$ 77,905	$ 72,724	$ 148,578	$ 142,198
Cost of sales	43,570	41,329	84,159	83,300
Gross profit	34,335	31,395	64,419	58,898
Operating expenses	27,654	26,270	52,605	49,143
Operating income	6,681	5,125	11,814	9,755
Interest expense, net	400	462	698	1,003
Income before provision for income taxes and loss on equity method investment	6,281	4,663	11,116	8,752
Income tax expense	1,681	1,234	3,061	2,294
Income before loss on equity method investment	4,600	3,429	8,055	6,458
Loss from equity method investment	69	47	111	129
Net income	4,531	3,382	7,944	6,329
Income attributable to non-controlling interest	(227)	(136)	(188)	(289)
Net income attributable to American Vanguard	$ 4,304	$ 3,246	$ 7,756	$ 6,040
Earnings per common share—basic	$ 0.15	$ 0.11	$ 0.27	$ 0.21
Earnings per common share—assuming dilution	$ 0.15	$ 0.11	$ 0.26	$ 0.21
Weighted average shares outstanding—basic	29,050	28,893	28,999	28,851
Weighted average shares outstanding—assuming dilution	29,605	29,377	29,561	29,342

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 4,531	$ 3,382	$ 7,944	$ 6,329
Comprehensive income:
Foreign currency translation adjustment	280	(537)	1,037	(452)
Comprehensive income	4,811	2,845	8,981	5,877
Income attributable to non-controlling interest	(227)	(136)	(188)	(289)
Comprehensive income attributable to American Vanguard	$ 4,584	$ 2,709	$ 8,793	$ 5,588

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 7,597	$ 7,869
Receivables:
Trade, net of allowance for doubtful accounts of $41 and $42, respectively	63,291	83,777
Other	3,912	3,429
Total receivables, net	67,203	87,206
Inventories	126,865	120,576
Prepaid expenses	12,609	11,424
Total current assets	214,274	227,075
Property, plant and equipment, net	50,383	50,295
Intangible assets, net of applicable amortization	130,806	121,433
Other assets	30,135	31,153
Total assets	425,598	429,956
Current liabilities:
Current installments of other liabilities	66	26
Accounts payable	25,560	24,358
Deferred revenue	1,722	3,848
Accrued program costs	61,749	42,930
Accrued expenses and other payables	7,988	12,072
Income taxes payable	1,063	13,840
Total current liabilities	98,148	97,074
Long-term debt, net of deferred loan fees	26,348	40,951
Other liabilities, excluding current installments	2,815	2,868
Deferred income tax liabilities	6,713	6,706
Total liabilities	134,024	147,599
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 32,212,124 shares at June 30, 2017 and 31,819,695 shares at December 31, 2016	3,222	3,183
Additional paid-in capital	72,768	71,699
Accumulated other comprehensive loss	(3,814)	(4,851)
Retained earnings	227,312	220,428
Total stockholders' equity including treasury stock	299,488	290,459
Less treasury stock at cost, 2,450,634 shares at June 30, 2017 and December 31, 2016	(8,269)	(8,269)
American Vanguard Corporation stockholders’ equity	291,219	282,190
Non-controlling interest	355	167
Total stockholders’ equity	291,574	282,357
Total liabilities and stockholders’ equity	$ 425,598	$ 429,956

CONDENSED CONSOLIDATED BALANCE5

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 41	$ 42
Preferred stock, par value per share	$ 0.10	$ 0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.10	$ 0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	32,212,124	31,819,695
Treasury stock, shares	2,450,634	2,450,634

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Retained Earnings	Treasury Stock	AVD Total	Non- Controlling Interest
Balance at Dec. 31, 2016	$ 282,357	$ 3,183	$ 71,699	$ (4,851)	$ 220,428	$ (8,269)	$ 282,190	$ 167
Balance (in shares) at Dec. 31, 2016	31,819,695	31,819,695				2,450,634
Stocks issued under ESPP	$ 250	$ 2	248				250
Stocks issued under ESPP (in shares)		16,349
Cash dividends on common stock ($0.015 per share)	(435)				(435)		(435)
Foreign currency translation adjustment, net	757			757			757
Stock based compensation	1,080		1,080				1,080
Stock options exercised; grants and vesting of restricted stock units	53	$ 37	16				53
Stock options exercised and grants, vesting and forfeited restricted stock units, Shares		377,916
Net income	3,413				3,452		3,452	(39)
Balance at Mar. 31, 2017	287,475	$ 3,222	73,043	(4,094)	223,445	$ (8,269)	287,347	128
Balance (in shares) at Mar. 31, 2017		32,213,960				2,450,634
Balance at Dec. 31, 2016	$ 282,357	$ 3,183	71,699	(4,851)	220,428	$ (8,269)	282,190	167
Balance (in shares) at Dec. 31, 2016	31,819,695	31,819,695				2,450,634
Foreign currency translation adjustment, net	$ 1,037
Net income	7,944
Balance at Jun. 30, 2017	$ 291,574	$ 3,222	72,768	(3,814)	227,312	$ (8,269)	291,219	355
Balance (in shares) at Jun. 30, 2017	32,212,124	32,212,124				2,450,634
Balance at Mar. 31, 2017	$ 287,475	$ 3,222	73,043	(4,094)	223,445	$ (8,269)	287,347	128
Balance (in shares) at Mar. 31, 2017		32,213,960				2,450,634
Cash dividends on common stock ($0.015 per share)	(437)				(437)		(437)
Foreign currency translation adjustment, net	280			280			280
Stock based compensation	1,242		1,242				1,242
Stock options exercised; grants and vesting of restricted stock units	(1,517)		(1,517)				(1,517)
Stock options exercised and grants, vesting and forfeited restricted stock units, Shares		(1,836)
Net income	4,531				4,304		4,304	227
Balance at Jun. 30, 2017	$ 291,574	$ 3,222	$ 72,768	$ (3,814)	$ 227,312	$ (8,269)	$ 291,219	$ 355
Balance (in shares) at Jun. 30, 2017	32,212,124	32,212,124				2,450,634

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Jun. 30, 2017	Mar. 31, 2017
Statement Of Stockholders Equity [Abstract]
Cash dividends on common stock, per share	$ 0.015	$ 0.015

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income	$ 7,944	$ 6,329
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of fixed and intangible assets	8,094	8,359
Amortization of other long term assets	2,777	2,358
Amortization of discounted liabilities	13	19
Stock-based compensation	2,322	1,068
Excess tax benefit from exercise of stock options		(47)
Increase in deferred income taxes	7
Loss from equity method investment	111	129
Changes in assets and liabilities associated with operations:
Decrease (increase) in net receivables	20,749	(4,156)
Increase in inventories	(5,506)	(14,625)
Increase in prepaid expenses and other assets	(2,658)	(2,661)
(Increase) decrease in income tax receivable/payable, net	(12,752)	1,244
Increase in accounts payable	579	9,837
Decrease in deferred revenue	(2,126)	(1,932)
Increase in program payables	18,819	17,956
(Decrease) increase in other payables and accrued expenses	(4,256)	1,612
Net cash provided by operating activities	34,117	25,490
Cash flows from investing activities:
Capital expenditures	(4,155)	(1,729)
Investment	(950)	(3,283)
Acquisition of product lines and other intangible assets	(13,400)	(224)
Net cash used in investing activities	(18,505)	(5,236)
Cash flows from financing activities:
Payments under line of credit agreement	(59,025)	(45,850)
Borrowings under line of credit agreement	45,000	27,000
Payments on other long-term liabilities	(26)	(457)
Tax benefit from exercise of stock options		47
Net payments from the issuance of common stock (sale of stock under ESPP, exercise of stock options, and shares purchased for tax withholding)	(1,214)	(195)
Payment of cash dividends	(724)
Net cash used in by financing activities	(15,989)	(19,455)
Net (decrease) increase in cash and cash equivalents	(377)	799
Effect of exchange rate changes on cash and cash equivalents	105	(524)
Cash and cash equivalents at beginning of period	7,869	5,524
Cash and cash equivalents at end of period	$ 7,597	$ 5,799

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2017
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	2. Property, plant and equipment at June 30, 2017 and December 31, 2016 consists of the following: June 30, 2017 December 31, 2016 Land $ 2,458 $ 2,458 Buildings and improvements 16,567 15,515 Machinery and equipment 107,278 102,146 Office furniture, fixtures and equipment 4,952 5,016 Automotive equipment 398 387 Construction in progress 1,324 8,047 Total gross value 132,977 133,569 Less accumulated depreciation (82,594 ) (83,274 ) Total net value $ 50,383 $ 50,295 The Company recognized depreciation expense related to property, plant and equipment of $2,129 and $2,059 for the three months ended June 30, 2017 and 2016, respectively. During the three months ended June 30, 2017 and 2016, the Company eliminated from assets and accumulated depreciation $3,584 and $2, respectively, of fully depreciated assets. The Company recognized depreciation expense related to property, plant and equipment of $4,079 and $4,313 for the six months ended June 30, 2017 and 2016, respectively. During the six months ended June 30, 2017 and 2016, the Company eliminated from assets and accumulated depreciation $4,759 and $125, respectively, of fully depreciated assets. Substantially all of the Company’s assets are pledged as collateral with its banks.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventories	3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following: June 30, 2017 December 31, 2016 Finished products $ 107,319 $ 103,832 Raw materials 19,546 16,744 $ 126,865 $ 120,576 As of June 30, 2017, we believe our inventories are valued at lower of cost or market. In July 2015, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASU”) 2015-11, Inventory (Topic 330). Topic 330 currently requires an entity to measure inventory at the lower of cost or market, where market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. This ASU limits the scope to inventory that is measured using first-in, first-out (FIFO) or average cost and requires inventory be measured at the lower of costs or net realizable value. The new standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this new standard effective January 1, 2017. There was no impact on this adoption.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Reporting	4. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Net sales: Insecticides $ 39,442 $ 30,912 $ 77,384 $ 64,018 Herbicides/soil fumigants/fungicides 16,045 21,093 36,066 45,767 Other, including plant growth regulators 10,096 6,331 13,488 9,820 Net sales: 65,583 58,336 126,938 119,605 Non-crop 12,322 14,388 21,640 22,593 Total net sales: $ 77,905 $ 72,724 $ 148,578 $ 142,198 Net sales: US $ 55,760 $ 51,773 $ 108,004 $ 101,628 International 22,145 20,951 40,574 40,570 Total net sales: $ 77,905 $ 72,724 $ 148,578 $ 142,198

Accrued Program Costs

Accrued Program Costs	6 Months Ended
	Jun. 30, 2017
Payables And Accruals [Abstract]
Accrued Program Costs	5. Accrued Program Costs

Cash Dividend

Cash Dividend	6 Months Ended
	Jun. 30, 2017
Cash Dividends [Abstract]
Cash Dividend	6. The Company has declared and paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid June 8, 2017 June 30, 2017 July 14, 2017 $ 0.015 $ 437 March 7, 2017 March 31, 2017 April 14, 2017 $ 0.015 $ 435 December 18, 2016 December 23, 2016 January 6, 2017 $ 0.010 $ 289

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share	7. ASC 260 Earnings Per Share (“EPS”) The components of basic and diluted earnings per share were as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Numerator: Net income attributable to AVD $ 4,304 $ 3,246 $ 7,756 $ 6,040 Denominator: (in thousands) Weighted average shares outstanding-basic 29,050 28,893 28,999 28,851 Dilutive effect of stock options and grants 555 484 562 491 29,605 29,377 29,561 29,342 For the three and six months ended June 30, 2017 and 2016, no stock options were excluded from the computation of diluted earnings per share.

Indebtedness

Indebtedness	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Indebtedness	8. The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at June 30, 2017 and December 31, 2016. The Company has no short term debt as of June 30, 2017 and December 31, 2016. These are summarized in the following table: Long-term indebtedness ($000's) June 30, 2017 December 31, 2016 Revolving line of credit $ 27,375 $ 41,400 Deferred loan fees (1,027 ) (449 ) Net long-term debt $ 26,348 $ 40,951 As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and Letter of Credit (“L/C”) issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250 million, an accordion feature of up to $100 million and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date. At June 30, 2017, according to the terms of the Credit Agreement and based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $143,182. This compares to an available borrowing capacity of $92,588 as of June 30, 2016. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve month period, which has improved, (2) net borrowings, which have decreased and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement).

Reclassification

Reclassification	6 Months Ended
	Jun. 30, 2017
Text Block [Abstract]
Reclassification	9. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the June 30, 2017 presentation.

Comprehensive income

Comprehensive income	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Comprehensive income	10. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three and six month periods ended June 30, 2017 and 2016, total comprehensive income consisted of net income attributable to American Vanguard and foreign currency translation adjustments.

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	11. Stock Based Compensation—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “ Share-Based Payment, The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three and six months ended June 30, 2017 and 2016. Stock-Based Compensation for the Three months ended Stock-Based Compensation for the Six months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) June 30, 2017 Incentive Stock Options $ 86 $ 170 $ 193 0.5 Restricted Stock 777 1,433 5,198 1.4 Performance Based Restricted Stock 321 621 2,157 2.3 Performance Based Options 58 98 117 0.5 Total $ 1,242 $ 2,322 $ 7,665 June 30, 2016 Incentive Stock Options $ 92 $ 181 $ 627 1.5 Restricted Stock 368 694 3,119 2.0 Performance Based Restricted Stock 107 140 1,079 2.8 Performance Based Options 45 53 226 1.5 Total $ 612 $ 1,068 $ 5,051 Stock Options—During the three and six months ended June 30, 2017, the Company did not grant any employees options to acquire shares of common stock. Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2016 541,905 $ 9.33 $ 7.97 Options exercised (15,000 ) 7.50 — Options forfeited (3,919 ) 11.49 — Balance outstanding, March 31, 2017 522,986 9.37 7.99 Options exercised (21,300 ) 7.50 — Options forfeited (3,183 ) 11.49 — Balance outstanding, June 30, 2017 498,503 $ 9.43 $ 8.03 Information relating to stock options at June 30, 2017, summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 262,050 41 $ 7.5 262,050 $ 7.50 $11.32—$14.49 236,453 86 $ 11.57 34,334 $ 12.07 498,503 $ 9.43 296,384 $ 8.03 The weighted average exercise prices for options granted, and exercisable, and the weighted average remaining contractual life for options outstanding as of June 30, 2017, were as follows: As of June 30, 2017 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Incentive Stock Option Plan: Outstanding 498,503 $ 9.43 63 $ 3,897 Expected to Vest 495,757 $ 9.42 62 $ 3,881 Exercisable 296,384 $ 8.03 44 $ 2,733 During the three months ended June 30, 2017 and 2016, the Company recognized stock-based compensation related to stock options of $86 and $92, respectively. During the six months ended June 30, 2017 and 2016, the Company recognized stock-based compensation related to stock options of $170 and $181, respectively. As of June 30, 2017, the Company had approximately $193 of unamortized stock-based compensation related to unvested stock options outstanding. This amount will be recognized over the weighted-average period of 0.5 years. This projected expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Common stock grants — Six Months Ended June 30, 2017 Six Months Ended June 30, 2016 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 324,756 $ 14.75 362,841 $ 20.43 Granted 251,475 16.10 — — Vested (10,100 ) 12.95 (127,274 ) 31.29 Forfeited (6,544 ) 15.26 (16,008 ) 23.67 Nonvested shares at March 31 st 559,587 15.38 219,559 14.59 Granted 38,502 17.08 140,541 15.08 Vested (188,400 ) 15.22 (22,639 ) 15.63 Forfeited (6,593 ) 15.55 (6,457 ) 14.98 Nonvested shares at June 30th 403,096 $ 15.61 331,004 $ 14.72 Common stock grants — During the six months ended June 30, 2017, the Company issued a total of 289,977 shares of common stock to employees and directors. 24,312 shares vested immediately, 3,900 shares will vest in three equal tranches on the employee’s anniversary, 1,000 shares will cliff vest after one year of service, 2,500 shares will cliff vest after two years of service, and the remaining shares will cliff vest after three years of service. The shares granted in 2017 were average fair valued at $16.23 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company will recognize as expense the value of restricted shares over the required service period. During the six months ended June 30, 2016, the Company issued a total of 140,541 shares of restricted common stock to employees. Of these, 21,139 shares vested immediately and the remaining 119,402 shares will cliff vest after three years of service. The shares granted in 2016 were average fair valued at $15.08 per share. The fair value was determined by using the publicly traded share price as of the date the grant was approved. The Company will recognize as expense the value of restricted shares over the required service period. During the three months ended June 30, 2017 and 2016, the Company recognized stock-based compensation related to restricted shares of $777 and $368, respectively. During the six months ended June 30, 2017 and 2016, the Company recognized stock-based compensation related to restricted shares of $1,433 and $694, respectively. As of June 30, 2017, the Company had approximately $5,198 of unamortized stock-based compensation related to unvested restricted shares. This amount will be recognized over the weighted-average period of 1.4 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Based Shares — Six Months Ended June 30, 2017 Six Months Ended June 30, 2016 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 119,022 $ 14.18 104,403 $ 17.05 Granted 121,194 15.40 — — Forfeited — — (9,395 ) 17.65 Nonvested shares at March 31 st 240,216 14.80 95,008 16.99 Granted 7,400 15.88 52,170 14.39 Vested (48,046 ) 14.92 — — Forfeited (12,560 ) 12.92 (19,612 ) 28.25 Nonvested shares at June 30th 187,010 $ 14.93 127,566 $ 14.20 Performance Based Shares — During the six months ended June 30, 2017, the Company issued a total of 128,594 performance based shares to employees. The shares granted during the six months of 2017 have an average fair value of $15.43. The fair value was determined by using the publicly traded share price as of the date of grant. The Company will recognize as expense the value of the performance based shares over the required service period from grant date. During the six months ended June, 2016, the Company conditionally granted a total of 52,170 performance based shares that will cliff vest on January 6, 2019 with a measurement period commencing January 1, 2016 and ending December 31, 2018. The shares granted to management during the first quarter of 2016, were subject to stockholder approval to extend the term of the Company’s stock incentive plan. That approval was received at the stockholder meeting on June 8, 2016. At that point the shares were given a fair value of $14.39. The fair value was determined by using publically traded share price on the date that the stockholders approved the grant. Eighty percent of these performance based shares are based upon the financial performance of the Company, specifically, EBIT goal weighted at 50% and a net sales goal weighted at 30%. The remaining 20% of performance based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goals measure the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The stockholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 2015 Proxy Statement. All parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for recording less than the targeted performance and to increase to a maximum of 200% for achieving in of the targeted performance. As the shares were subject to stockholder approval at the time the shares were issued to management, no expense was recorded during the first quarter of 2016. As of June 30, 2017, performance based shares related to EBIT and net sales have an average fair value of $16.10 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $12.60 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period. During the three months ended June 30, 2017 and 2016, the Company recognized stock-based compensation related to performance based shares of $321 and $107, respectively. During the six months ended June 30, 2017 and 2016, the Company recognized stock-based compensation related to performance based shares of $621 and $140, respectively. As of June 30, 2017, the Company had approximately $2,157 of unamortized stock-based compensation expense related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.3 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Incentive Stock Options—During the six months ended June 30, 2017 and 2016, the Company did not grant any employees performance incentive stock options to acquire shares of common stock. Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2016 82,334 $ 11.49 $ — Options forfeited — — — Balance outstanding, March 31, 2017 82,334 11.49 — Options forfeited (50 ) 11.49 — Balance outstanding, June 30, 2017 82,284 $ 11.49 $ — Information relating to stock options at June 30, 2017 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: 82,284 6 $ 11.49 — $ — The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2017 are as follows: As of June 30, 2017 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Performance Incentive Stock Option Plan: Outstanding 82,284 $ 11.49 6 $ 474 Expected to Vest 78,672 $ 11.49 6 $ 453 Exercisable — $ — — $ — During the three months ended June 30, 2017 and 2016, the Company recognized stock-based compensation related to performance stock options of $58 and $45, respectively. During the six months ended June 30, 2017 and 2016, the Company recognized stock-based compensation related to performance stock options of $98 and $53, respectively. As of June 30, 2017, the Company had approximately $117 of unamortized stock-based compensation expenses related to unvested performance incentive stock options outstanding. This amount will be recognized over the weighted-average period of 0.5 and 1.5 years. This projected expense will change if any performance incentive stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. In March 2016, FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718)

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Legal Proceedings	12. Legal Proceedings— During the reporting period, there have been no material developments in legal proceedings that are pending or threatened against the Company, except as described below. On November 10, 2016, the Company was served with a grand jury subpoena out of the U.S. District Court for the Southern District of Alabama in which both the Environmental Crimes Section (“ECS”) of USEPA and the U.S. Department of Justice (“DoJ”) are seeking the production of documents relating to the re-importation of depleted Thimet containers between 2011 and 2016. The Company has retained defense counsel and is cooperating with both ECS and DoJ in the production. During the three month and six month periods ended June 30, 2017, significant legal costs have been expended in connection with this activity. At this stage, ECS and DoJ have not made clear their intentions with regard to any potential criminal enforcement. Thus, it is too early to tell whether a loss on either front is probable or reasonably estimable. Accordingly, the Company has not recorded a loss contingency on these matters. Delaware DBCP Cases. Abad Castillo Marquinez Walker v. AMVAC. Larry L. Walker v. Amvac Chemical Corporation

Recently Issued Accounting Guid

Recently Issued Accounting Guidance	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Recently Issued Accounting Guidance	13. Recently Issued Accounting Guidance— In November 2016, FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230). In October 2016 FASB issued ASU 2016-16, Income Taxes (Topic 740). In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) In February 2016, FASB issued ASU 2016-02, Leases In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers We have completed an initial scoping analysis of the effect of the standards to identify the revenue streams that may be affected by this ASU. The Company is evaluating if the adoption could result in a change in the timing of recognizing revenue for certain products from point in time, to over time, due to the creation of goods with no alternative use accompanied by an enforceable right to payment. The Company is continuing to evaluate the impact the adoption of this new guidance will have on these and other revenue transactions. The Company is currently evaluating which transition approach to use and assessing the effect the adoption of ASU2014-09 may have on our financial condition, results of operations or cash flows. The Company expects to adopt the new revenue recognition standard for the financial year beginning January 1, 2018.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	14. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt payable to the bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt payable to bank.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income ("AOCI")	6 Months Ended
	Jun. 30, 2017
Text Block [Abstract]
Accumulated Other Comprehensive Income ("AOCI")	15. Accumulated Other Comprehensive Income (“AOCI”) — Total Balance, December 31, 2016 $ (4,851 ) FX translation 757 Balance, March 31, 2017 (4,094 ) FX translation 280 Balance, June 30, 2017 $ (3,814 )

Equity Investment

Equity Investment	6 Months Ended
	Jun. 30, 2017
Tyra Tech Inc
Equity Investment	16. TyraTech Inc. (“TyraTech”) is a Delaware corporation that specializes in developing, marketing and selling pesticide products containing natural oils. As of June 30, 2017, the Company’s ownership position in TyraTech was approximately 15.11%. The Company utilizes the equity method of accounting with respect to this investment. As a result, our net income includes losses from equity method investments, which represents our proportionate share of TyraTech’s estimated net losses for the current accounting period. For the three and six months ended June 30, 2017, the Company recognized a loss of $69 and $111 as a result of the Company’s ownership position in TyraTech. The Company recognized a loss of $47 and $129 for the three and six months ended June 30, 2016. The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheets. At June 30, 2017, the carrying value of the Company’s investment in TyraTech was $2,073 and the quoted market value of its shareholding was $820 based on the London Stock Exchange, Alternative Investment Market (“AIM”). At June 30, 2017, the Company performed an impairment review of its investment in TyraTech and concluded that the implied decrease in value was not other than temporary and no impairment charge was required.

Cost Method Investment

Cost Method Investment	6 Months Ended
	Jun. 30, 2017
Biological Products For Agriculture
Cost Method Investment	17. In February 2016, the Company made an equity investment in Biological Products for Agriculture (“Bi-PA”) through its Netherlands wholly-owned subsidiary. Bi-PA develops biological plant protection products that can be used for the control of pests and disease of agricultural crops. As of June 30, 2017, the Company’s ownership position in Bi-PA is 15%. The Company utilizes the cost method of accounting with respect to this investment and will periodically review the investment for possible impairment. There was no impairment on the investment as of June 30, 2017. The investment is recorded within other assets on the condensed consolidated balance sheets.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	18. Income Taxes – Income tax expense increased by $447 to end at an expense of $1,681 for the three months ended June 30, 2017, as compared to $1,234 for the comparable period in 2016. The effective tax rate for the quarter was 26.8%, as compared to 26.5% in the same period of the prior year. Income tax expense was $3,061 for the six months ended June 30, 2017, as compared to $2,294 for the six months ended June 30, 2016. The effective tax rate for the six months ended June 30, 2017 and 2016 was 27.5% and 26.2%, respectively. The effective tax rate is based on the projected income for the full year and is subject to ongoing review and adjustment by management. During the first quarter of 2017, the Company adopted ASU 2016-09, “Improvement to Employee Share-Based Payment Accounting,” which simplifies several aspects of the accounting for share-based payments, including treatment of excess tax benefits and forfeitures, as well as consideration of minimum statutory tax withholding requirements. Under the new standard, all excess tax benefits and tax deficiencies will be recognized as income tax expense or benefit in the income statement as discrete items in the reporting period in which they occur. For the six months year to date, a discrete tax benefit of $280 was recognized as part of the income tax expense. The Company has effectively settled its examination with the Internal Revenue Service (“IRS”) for the tax years ended December 31, 2013 and 2014. As a result, the Company increased deferred tax assets and income taxes payable at December 31, 2016 by $12,598. The Company’s 2015 federal income tax return is still subject to IRS examination. The Company’s state income tax returns are subject to examination for the 2012 through 2015 tax years. On April 3, 2017, the Company paid the IRS $11,580.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Acquisitions	19. On June 6, 2017, the Company’s principal operating subsidiary, Amvac Chemical Corporation, completed an acquisition of certain assets relating to the abamectin, chlorothalonil and paraquat product lines from a group of companies, including Adama Agricultural Solutions, Ltd. The consideration for the acquired assets was paid in cash and has initially been fully allocated to inventory and intangible assets. The Company expects to finalize its allocations in accordance with ASC 805 during the third quarter of 2017. The acquisitions were made because the acquired products fit with the Company’s strategy to provide growers with a complete range of chemical solutions. The contribution of the acquired products was included in the Company’s result of operation from June 6, 2017 (the date of acquisition) and in the condensed consolidated balance sheet as of June 30, 2017. The purchase price is not material to the condensed consolidated financial statements. For the three and six months ended June 30, 2017, the proforma results are not provided because the amounts are not material to the Company’s revenues, cash flows and net income.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Event	20. Subsequent Event – On June 27, 2017, both Amvac Netherlands BV and Huifeng Agrochemical Company, Ltd made individual capital contributions of $950 to the Hong Kong Joint Venture (“Huifeng Amvac Innovation Co. Ltd”), which is recorded as an equity investment in the Company’s condensed consolidated financial statements. No material investment or other transactions have been entered into (by the Hong Kong Joint Venture) as of June 30, 2017. On July 7, 2017, our Hong Kong Joint Venture purchased the shares of Profeng Australia, Pty Ltd., for a total consideration of $1,900. The purchase consists of Profeng Australia, Pty Ltd Trustee and Profeng Australia Unit Trust. Both Trust and Trustee were previously owned by Huifeng via its wholly owned subsidiary Shanghai Biological Focus center.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2017
Property Plant And Equipment [Abstract]
Summary of Property, Plant and Equipment	Property, plant and equipment at June 30, 2017 and December 31, 2016 consists of the following: June 30, 2017 December 31, 2016 Land $ 2,458 $ 2,458 Buildings and improvements 16,567 15,515 Machinery and equipment 107,278 102,146 Office furniture, fixtures and equipment 4,952 5,016 Automotive equipment 398 387 Construction in progress 1,324 8,047 Total gross value 132,977 133,569 Less accumulated depreciation (82,594 ) (83,274 ) Total net value $ 50,383 $ 50,295

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Components of Inventories	The components of inventories consist of the following: June 30, 2017 December 31, 2016 Finished products $ 107,319 $ 103,832 Raw materials 19,546 16,744 $ 126,865 $ 120,576

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Summary of Business Sales Segmentation	Selective enterprise information is as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Net sales: Insecticides $ 39,442 $ 30,912 $ 77,384 $ 64,018 Herbicides/soil fumigants/fungicides 16,045 21,093 36,066 45,767 Other, including plant growth regulators 10,096 6,331 13,488 9,820 Net sales: 65,583 58,336 126,938 119,605 Non-crop 12,322 14,388 21,640 22,593 Total net sales: $ 77,905 $ 72,724 $ 148,578 $ 142,198 Net sales: US $ 55,760 $ 51,773 $ 108,004 $ 101,628 International 22,145 20,951 40,574 40,570 Total net sales: $ 77,905 $ 72,724 $ 148,578 $ 142,198

Cash Dividend (Tables)

Cash Dividend (Tables)	6 Months Ended
	Jun. 30, 2017
Cash Dividends [Abstract]
Cash Dividend	The Company has declared and paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid June 8, 2017 June 30, 2017 July 14, 2017 $ 0.015 $ 437 March 7, 2017 March 31, 2017 April 14, 2017 $ 0.015 $ 435 December 18, 2016 December 23, 2016 January 6, 2017 $ 0.010 $ 289

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Components of Basic and Diluted Earnings Per Share	The components of basic and diluted earnings per share were as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Numerator: Net income attributable to AVD $ 4,304 $ 3,246 $ 7,756 $ 6,040 Denominator: (in thousands) Weighted average shares outstanding-basic 29,050 28,893 28,999 28,851 Dilutive effect of stock options and grants 555 484 562 491 29,605 29,377 29,561 29,342

Indebtedness (Tables)

Indebtedness (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Summary of Revolving Line of Credit	The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at June 30, 2017 and December 31, 2016. The Company has no short term debt as of June 30, 2017 and December 31, 2016. These are summarized in the following table: Long-term indebtedness ($000's) June 30, 2017 December 31, 2016 Revolving line of credit $ 27,375 $ 41,400 Deferred loan fees (1,027 ) (449 ) Net long-term debt $ 26,348 $ 40,951

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Stock Based Compensation, Unamortized Stock-Based Compensation and Remaining Weighted Average Period	The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three and six months ended June 30, 2017 and 2016. Stock-Based Compensation for the Three months ended Stock-Based Compensation for the Six months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) June 30, 2017 Incentive Stock Options $ 86 $ 170 $ 193 0.5 Restricted Stock 777 1,433 5,198 1.4 Performance Based Restricted Stock 321 621 2,157 2.3 Performance Based Options 58 98 117 0.5 Total $ 1,242 $ 2,322 $ 7,665 June 30, 2016 Incentive Stock Options $ 92 $ 181 $ 627 1.5 Restricted Stock 368 694 3,119 2.0 Performance Based Restricted Stock 107 140 1,079 2.8 Performance Based Options 45 53 226 1.5 Total $ 612 $ 1,068 $ 5,051
Summary of Option Activity	Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2016 541,905 $ 9.33 $ 7.97 Options exercised (15,000 ) 7.50 — Options forfeited (3,919 ) 11.49 — Balance outstanding, March 31, 2017 522,986 9.37 7.99 Options exercised (21,300 ) 7.50 — Options forfeited (3,183 ) 11.49 — Balance outstanding, June 30, 2017 498,503 $ 9.43 $ 8.03
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at June 30, 2017, summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 262,050 41 $ 7.5 262,050 $ 7.50 $11.32—$14.49 236,453 86 $ 11.57 34,334 $ 12.07 498,503 $ 9.43 296,384 $ 8.03
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted, and exercisable, and the weighted average remaining contractual life for options outstanding as of June 30, 2017, were as follows: As of June 30, 2017 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Incentive Stock Option Plan: Outstanding 498,503 $ 9.43 63 $ 3,897 Expected to Vest 495,757 $ 9.42 62 $ 3,881 Exercisable 296,384 $ 8.03 44 $ 2,733
Performance Based Stock Options
Summary of Option Activity	Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2016 82,334 $ 11.49 $ — Options forfeited — — — Balance outstanding, March 31, 2017 82,334 11.49 — Options forfeited (50 ) 11.49 — Balance outstanding, June 30, 2017 82,284 $ 11.49 $ —
Performance Incentive Stock Option Plan
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at June 30, 2017 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: 82,284 6 $ 11.49 — $ —
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2017 are as follows: As of June 30, 2017 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Performance Incentive Stock Option Plan: Outstanding 82,284 $ 11.49 6 $ 474 Expected to Vest 78,672 $ 11.49 6 $ 453 Exercisable — $ — — $ —
Common Stock Grants
Summary of Non-Vested Shares	Common stock grants — Six Months Ended June 30, 2017 Six Months Ended June 30, 2016 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 324,756 $ 14.75 362,841 $ 20.43 Granted 251,475 16.10 — — Vested (10,100 ) 12.95 (127,274 ) 31.29 Forfeited (6,544 ) 15.26 (16,008 ) 23.67 Nonvested shares at March 31 st 559,587 15.38 219,559 14.59 Granted 38,502 17.08 140,541 15.08 Vested (188,400 ) 15.22 (22,639 ) 15.63 Forfeited (6,593 ) 15.55 (6,457 ) 14.98 Nonvested shares at June 30th 403,096 $ 15.61 331,004 $ 14.72
Performance Based Restricted Shares
Summary of Non-Vested Shares	Performance Based Shares — Six Months Ended June 30, 2017 Six Months Ended June 30, 2016 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 119,022 $ 14.18 104,403 $ 17.05 Granted 121,194 15.40 — — Forfeited — — (9,395 ) 17.65 Nonvested shares at March 31 st 240,216 14.80 95,008 16.99 Granted 7,400 15.88 52,170 14.39 Vested (48,046 ) 14.92 — — Forfeited (12,560 ) 12.92 (19,612 ) 28.25 Nonvested shares at June 30th 187,010 $ 14.93 127,566 $ 14.20

Accumulated Other Comprehensi36

Accumulated Other Comprehensive Income ("AOCI") (Tables)	6 Months Ended
	Jun. 30, 2017
Text Block [Abstract]
Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss	The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments: Total Balance, December 31, 2016 $ (4,851 ) FX translation 757 Balance, March 31, 2017 (4,094 ) FX translation 280 Balance, June 30, 2017 $ (3,814 )

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total gross value	$ 132,977	$ 133,569
Less accumulated depreciation	(82,594)	(83,274)
Total net value	50,383	50,295
Land
Property, Plant and Equipment [Line Items]
Total gross value	2,458	2,458
Buildings and improvements
Property, Plant and Equipment [Line Items]
Total gross value	16,567	15,515
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total gross value	107,278	102,146
Office furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Total gross value	4,952	5,016
Automotive equipment
Property, Plant and Equipment [Line Items]
Total gross value	398	387
Construction in progress
Property, Plant and Equipment [Line Items]
Total gross value	$ 1,324	$ 8,047

Property, Plant And Equipment -

Property, Plant And Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Property Plant And Equipment [Abstract]
Depreciation expense related to property, plant and equipment	$ 2,129	$ 2,059	$ 4,079	$ 4,313
Elimination of Assets and Accumulated depreciation	$ 3,584	$ 2	$ 4,759	$ 125

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished products	$ 107,319	$ 103,832
Raw materials	19,546	16,744
Total Inventories	$ 126,865	$ 120,576

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2017Segment
Segment Reporting [Abstract]
Number of reportable business segments	1

Summary of Business Sales by Pr

Summary of Business Sales by Product and Geographic Location (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net sales
Net sales	$ 77,905	$ 72,724	$ 148,578	$ 142,198
Insecticides
Net sales
Net sales	39,442	30,912	77,384	64,018
Herbicides/Soil Fumigants/Fungicides
Net sales
Net sales	16,045	21,093	36,066	45,767
Other, Including Plant Growth Regulators
Net sales
Net sales	10,096	6,331	13,488	9,820
Crop
Net sales
Net sales	65,583	58,336	126,938	119,605
Non-Crop
Net sales
Net sales	12,322	14,388	21,640	22,593
US
Net sales
Net sales	55,760	51,773	108,004	101,628
International
Net sales
Net sales	$ 22,145	$ 20,951	$ 40,574	$ 40,570

Cash Dividend (Detail)

Cash Dividend (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Cash dividend declaration date	Jun. 8, 2017	Mar. 7, 2017	Dec. 18, 2016
Cash dividend record date	Jun. 30, 2017	Mar. 31, 2017	Dec. 23, 2016
Cash dividend distributed date	Jul. 14, 2017	Apr. 14, 2017	Jan. 6, 2017
Cash dividend per share	$ 0.015	$ 0.015	$ 0.010
Cash dividend paid	$ 437	$ 435	$ 289

Components of Basic and Diluted

Components of Basic and Diluted Earnings Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Numerator:
Net income attributable to AVD	$ 4,304	$ 3,246	$ 7,756	$ 6,040
Denominator:
Weighted average shares outstanding-basic	29,050	28,893	28,999	28,851
Dilutive effect of stock options and grants	555	484	562	491
Weighted average shares outstanding-assuming dilution	29,605	29,377	29,561	29,342

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Stock options excluded from computation of diluted earning per share	0	0	0	0

Indebtedness - Additional Infor

Indebtedness - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016
Debt Instrument [Line Items]
Short term debt	$ 0	$ 0
Senior secured credit facility, maturity date	Jun. 30, 2022
Revolving Line of Credit
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement			$ 92,588,000
Maximum
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement	$ 250,000,000
Consolidated funded debt ratio	325.00%
Maximum | Revolving Line of Credit
Debt Instrument [Line Items]
Capacity to increase borrowings under credit agreement	$ 143,182,000
Maximum | Term Loan
Debt Instrument [Line Items]
Accordion feature	$ 100,000,000
Minimum
Debt Instrument [Line Items]
Consolidated fixed charge covenant ratio	125.00%

Summary of Revolving Line of Cr

Summary of Revolving Line of Credit (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Revolving line of credit	$ 27,375	$ 41,400
Deferred loan fees	(1,027)	(449)
Net long-term debt	$ 26,348	$ 40,951

Unamortized Stock-Based Compens

Unamortized Stock-Based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 1,242	$ 612	$ 2,322	$ 1,068
Unamortized Stock-Based Compensation	7,665	5,051	7,665	5,051
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	86	92	$ 170	$ 181
Remaining Weighted Average Period (years)			6 months	1 year 6 months
Unamortized Stock-Based Compensation	193	627	$ 193	$ 627
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	777	368	$ 1,433	$ 694
Remaining Weighted Average Period (years)			1 year 4 months 24 days	2 years
Unamortized Stock-Based Compensation	5,198	3,119	$ 5,198	$ 3,119
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	321	107	$ 621	$ 140
Remaining Weighted Average Period (years)			2 years 3 months 19 days	2 years 9 months 18 days
Unamortized Stock-Based Compensation	2,157	1,079	$ 2,157	$ 1,079
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	58	45	$ 98	$ 53
Remaining Weighted Average Period (years)			6 months	1 year 6 months
Unamortized Stock-Based Compensation	$ 117	$ 226	$ 117	$ 226

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($)	Jun. 08, 2016	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employees options granted		0				0
Stock-based compensation		$ 1,242,000		$ 612,000		$ 2,322,000	$ 1,068,000
Number of shares granted to employees and directors						289,977
Number of shares vested						24,312
Number of shares expected to vest		3,900				3,900
Number of years of service before cliff vesting						3 years
Weighted Average Grant-Date Fair Value, Granted						$ 16.23
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 58,000		45,000		$ 98,000	$ 53,000
Nonvested unamortized stock-based compensation expense, value		$ 117,000				$ 117,000
Remaining Weighted Average Period (years)						6 months	1 year 6 months
Number of shares granted to employees and directors						0	0
After One Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest		1,000				1,000
After Two Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest		2,500				2,500
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 86,000		92,000		$ 170,000	$ 181,000
Nonvested unamortized stock-based compensation expense, value		193,000		627,000		$ 193,000	$ 627,000
Remaining Weighted Average Period (years)						6 months	1 year 6 months
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 777,000		$ 368,000		$ 1,433,000	$ 694,000
Remaining Weighted Average Period (years)						1 year 4 months 24 days	2 years
Number of shares granted to employees and directors		38,502	251,475	140,541
Number of shares vested		188,400	10,100	22,639	127,274		21,139
Number of years of service before cliff vesting							3 years
Weighted Average Grant-Date Fair Value, Granted		$ 17.08	$ 16.10	$ 15.08			$ 15.08
Shares issued by equity investee							140,541
Unamortized Stock-Based Compensation		$ 5,198,000		$ 3,119,000		$ 5,198,000	$ 3,119,000
Restricted Stock | After Three Year of Services.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest				119,402			119,402
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 321,000		$ 107,000		$ 621,000	$ 140,000
Remaining Weighted Average Period (years)						2 years 3 months 19 days	2 years 9 months 18 days
Number of shares granted to employees and directors		7,400	121,194	52,170		128,594	52,170
Number of shares vested		48,046
Weighted Average Grant-Date Fair Value, Granted	$ 14.39	$ 15.88	$ 15.40	$ 14.39		$ 15.43
Unamortized Stock-Based Compensation		$ 2,157,000		$ 1,079,000		$ 2,157,000	$ 1,079,000
Targeted performance percentage		200.00%		200.00%		200.00%	200.00%
Performance Based Restricted Stock | Subject To Stockholder Approval
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation							$ 0
Performance Based Restricted Stock | Vested on February 8, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cliff vesting date						Feb. 8, 2020	Jan. 6, 2019
Performance Based Restricted Stock | Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2017 through December 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance						80.00%
Earnings before income taxes goal weight, percentage						50.00%
Net sales goal weight, percentage						30.00%
Performance Based Restricted Stock | Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2017 through December 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income taxes goal weight, percentage						20.00%
Performance Based Restricted Stock | Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2016 and ending December 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance							80.00%
Earnings before income taxes goal weight, percentage							50.00%
Net sales goal weight, percentage							30.00%
Performance Based Restricted Stock | Performance based stock options based upon AVD stock price appreciation over the course of the period commencing January 1, 2016 and ending December 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income taxes goal weight, percentage							20.00%
Performance Based Restricted Stock | Performance Based Shares Related to Net Income Weighted at 50%, Net Sales Weighted at 30%, Commencing January 1, 2017 and Ending December 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted						$ 16.10
Performance Based Restricted Stock | Remaining 20% of Performance Based Shares are Based Upon AVD Stock Price Appreciation for the Period Commencing January 1, 2017 and Ending December 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted						$ 12.60

Summary of Option Activity (Det

Summary of Option Activity (Detail) - Incentive Stock Options - $ / shares	3 Months Ended
	Jun. 30, 2017	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	522,986	541,905
Incentive Stock Option Plans, Option exercised	21,300	(15,000)
Incentive Stock Option Plans, Option forfeited	(3,183)	(3,919)
Incentive Stock Option Plans, Ending balance	498,503	522,986
Weighted Average Price Per Share, Beginning balance	$ 9.37	$ 9.33
Weighted Average Price Per Share, Option exercised	7.50	7.50
Weighted Average Price Per Share, Option forfeited	11.49	11.49
Weighted Average Price Per Share, Ending balance	9.43	9.37
Exercisable Weighted Average Price Per Share, Beginning balance	7.99	7.97
Exercisable Weighted Average Price Per Share, Ending balance	$ 8.03	$ 7.99

Summary of Stock Options Summar

Summary of Stock Options Summarized by Exercise Price (Detail) - Incentive Stock Options - $ / shares	6 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	498,503
Outstanding Weighted Average, Exercise Price	$ 9.43	$ 9.37	$ 9.33
Exercisable Weighted Average, Shares	296,384
Exercisable Weighted Average, Exercise Price	$ 8.03	$ 7.99	$ 7.97
Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$ 7.50
Outstanding Weighted Average, Shares	262,050
Outstanding Weighted Average, Remaining Life (Months)	41 months
Outstanding Weighted Average, Exercise Price	$ 7.5
Exercisable Weighted Average, Shares	262,050
Exercisable Weighted Average, Exercise Price	$ 7.50
Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	11.32
Exercise Price Per Share, Upper Range	$ 14.49
Outstanding Weighted Average, Shares	236,453
Outstanding Weighted Average, Remaining Life (Months)	86 months
Outstanding Weighted Average, Exercise Price	$ 11.57
Exercisable Weighted Average, Shares	34,334
Exercisable Weighted Average, Exercise Price	$ 12.07

Weighted Average Exercise Price

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Expected to Vest	3,900
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	498,503
Number of Shares, Expected to Vest	495,757
Number of Shares, Exercisable	296,384
Weighted Average Exercise Price, Outstanding | $ / shares	$ 9.43
Weighted Average Exercise Price, Expected to Vest | $ / shares	9.42
Weighted Average Exercisable, Exercise Price | $ / shares	$ 8.03
Weighted Average Remaining Life, Outstanding	63 months
Weighted Average Remaining Contractual Life, Expected to Vest	62 months
Weighted Average Remaining Contractual Life, Exercisable	44 months
Intrinsic Value, Outstanding | $	$ 3,897
Intrinsic Value, Expected to Vest | $	3,881
Intrinsic Value, Exercisable | $	$ 2,733

Summary of Non-Vested Shares (D

Summary of Non-Vested Shares (Detail) - $ / shares	3 Months Ended				6 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted					289,977
Number of Shares, Vested					(24,312)
Weighted Average Grant-Date Fair Value, Granted					$ 16.23
Common Stock Grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	559,587	324,756	219,559	362,841	324,756	362,841
Number of Shares, Granted	38,502	251,475	140,541
Number of Shares, Vested	(188,400)	(10,100)	(22,639)	(127,274)		(21,139)
Number of Shares, Forfeited	(6,593)	(6,544)	(6,457)	(16,008)
Number of Shares, Ending Balance	403,096	559,587	331,004	219,559	403,096	331,004
Weighted Average Grant-Date Fair Value, Beginning balance	$ 15.38	$ 14.75	$ 14.59	$ 20.43	$ 14.75	$ 20.43
Weighted Average Grant-Date Fair Value, Granted	17.08	16.10	15.08			15.08
Weighted Average Grant-Date Fair Value, Vested	15.22	12.95	15.63	31.29
Weighted Average Grant-Date Fair Value, Forfeited	15.55	15.26	14.98	23.67
Weighted Average Grant-Date Fair Value, Ending balance	$ 15.61	$ 15.38	$ 14.72	$ 14.59	$ 15.61	$ 14.72

Status Summary of Non-Vested Sh

Status Summary of Non-Vested Shares (Detail) - $ / shares	Jun. 08, 2016	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted						289,977
Number of Shares, Vested						(24,312)
Weighted Average Grant-Date Fair Value, Granted						$ 16.23
Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance		240,216	119,022	95,008	104,403	119,022	104,403
Number of Shares, Granted		7,400	121,194	52,170		128,594	52,170
Number of Shares, Vested		(48,046)
Number of Shares, Forfeited		(12,560)		(19,612)	(9,395)
Number of Shares, Ending Balance		187,010	240,216	127,566	95,008	187,010	127,566
Weighted Average Grant-Date Fair Value, Beginning balance		$ 14.80	$ 14.18	$ 16.99	$ 17.05	$ 14.18	$ 17.05
Weighted Average Grant-Date Fair Value, Granted	$ 14.39	15.88	15.40	14.39		15.43
Weighted Average Grant-Date Fair Value, Vested		14.92
Weighted Average Grant-Date Fair Value, Forfeited		12.92		28.25	17.65
Weighted Average Grant-Date Fair Value, Ending balance		$ 14.93	$ 14.80	$ 14.20	$ 16.99	$ 14.93	$ 14.20

Summary of Performance option a

Summary of Performance option activity (Detail) - Performance Based Stock Options - $ / shares	3 Months Ended
	Jun. 30, 2017	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	82,334	82,334
Incentive Stock Option Plans, Option forfeited	(50)	0
Incentive Stock Option Plans, Ending balance	82,284	82,334
Weighted Average Price Per Share, Beginning balance	$ 11.49	$ 11.49
Weighted Average Price Per Share, Option forfeited	11.49	0
Weighted Average Price Per Share, Ending balance	$ 11.49	$ 11.49

Performance Options Summarized

Performance Options Summarized by Exercise Price (Detail) - Performance Incentive Stock Option Plan	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares | shares	82,284
Outstanding Weighted Average, Remaining Life (Months)	6 months
Outstanding Weighted Average, Exercise Price | $ / shares	$ 11.49

Performance Option Weighted Ave

Performance Option Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Expected to Vest	3,900
Performance Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	82,284
Number of Shares, Expected to Vest	78,672
Weighted Average Exercise Price, Outstanding | $ / shares	$ 11.49
Weighted Average Exercise Price, Expected to Vest | $ / shares	$ 11.49
Weighted Average Remaining Life, Outstanding	6 months
Weighted Average Remaining Contractual Life, Expected to Vest	6 months
Intrinsic Value, Outstanding | $	$ 474
Intrinsic Value, Expected to Vest | $	$ 453

Legal Proceedings - Additional

Legal Proceedings - Additional Information (Detail)	Jun. 18, 2017Case	Sep. 19, 2013Case	Jun. 30, 2017CaseEmployee
Commitments And Contingencies Disclosure [Abstract]
Number of lawsuits filed			2
Number of banana plantation workers | Employee			2,700
Number of plaintiffs dismissed		14
Number of plaintiffs	57	22

Beginning Balance, Annual Activ

Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 287,475	$ 282,357		$ 282,357
Foreign currency translation adjustment	280	757	$ (537)	1,037	$ (452)
Balance	291,574	287,475		291,574
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(4,094)	(4,851)		(4,851)
Foreign currency translation adjustment	280	757
Balance	$ (3,814)	$ (4,094)		$ (3,814)

Equity Method Investment - Addi

Equity Method Investment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Equity Method Investments [Line Items]
Loss from equity method investment	$ (69)	$ (47)	$ (111)	$ (129)
Tyra Tech Inc
Equity Method Investments [Line Items]
Equity investment ownership position	15.11%		15.11%
Loss from equity method investment	$ (69)	$ (47)	$ (111)	$ (129)
Carrying value of equity investment	2,073		2,073
Quoted market value of equity investment	$ 820		$ 820

Cost Method Investment - Additi

Cost Method Investment - Additional Information (Detail) - Bi-PA	6 Months Ended
	Jun. 30, 2017USD ($)
Schedule of Cost-method Investments [Line Items]
Cost method ownership percentage	15.00%
Cost-method Investments, Impairment	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 03, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Income Taxes [Line Items]
Increase in income tax expense		$ 447
Income tax expense		$ 1,681	$ 1,234	$ 3,061	$ 2,294
Effective tax rate		26.80%	26.50%	27.50%	26.20%
Internal Revenue Service
Income Taxes [Line Items]
Amount paid to IRS	$ 11,580
Deferred Tax Assets And Income Taxes Payable
Income Taxes [Line Items]
Prior period reclassification adjustment						$ 12,598
State and Local Jurisdiction | Minimum
Income Taxes [Line Items]
Income Tax Examination Period				2,012
State and Local Jurisdiction | Maximum
Income Taxes [Line Items]
Income Tax Examination Period				2,015
ASU 2016-09
Income Taxes [Line Items]
Discrete tax benefit				$ (280)

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - Hong Kong Joint Venture - USD ($) $ in Thousands	Jul. 07, 2017	Jun. 27, 2017
Subsequent Event [Line Items]
Individual capital contributions		$ 950
Profeng Australia, Pty Ltd | Subsequent Event
Subsequent Event [Line Items]
Joint venture, consideration	$ 1,900